Quiet on the insider front: nobody at Fortress Biotech, Inc. bought or sold FBIO shares in open-market trades this past year.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Big money check: 55 institutions held FBIO as of Q2 2026, and funds were split between buying and selling.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 25, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 763,359 | $1.84 | $1.4M | SEC |
| Jul 15, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 5,000 | $7.48 | $37K | SEC |
| Jul 12, 2024 | Jin David | CFO | Buy | 500 | $7.50 | $4K | SEC |
| Jul 11, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 5,000 | $7.39 | $37K | SEC |
| Jul 10, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 5,000 | $7.35 | $37K | SEC |
| Jul 1, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 20,000 | $1.64 | $33K | SEC |
| May 20, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 10,000 | $1.76 | $18K | SEC |
| May 20, 2024 | Klein Dov | Director | Sell | 10,000 | $1.89 | $19K | SEC |
| Jan 9, 2024 | ROSENWALD LINDSAY A MD | CEO | Buy | 50,000 | $2.38 | $119K | SEC |
| Nov 16, 2023 | ROSENWALD LINDSAY A MD | CEO | Buy | 1,567,515 | $1.70 | $2.7M | SEC |
| Nov 16, 2023 | WEISS MICHAEL S | Officer | Buy | 147,058 | $1.70 | $250K | SEC |
| Aug 21, 2023 | ROSENWALD LINDSAY A MD | CEO | Buy | 10,000 | $11.75 | $118K | SEC |
| Aug 21, 2023 | ROSENWALD LINDSAY A MD | CEO | Buy | 10,000 | $9.34 | $93K | SEC |
| Feb 14, 2023 | Rowinsky Eric K | Director | Buy | 11,976 | $0.84 | $10K | SEC |
| Feb 14, 2023 | LOBELL J JAY | Director | Buy | 299,401 | $0.84 | $251K | SEC |
There were no open-market insider trades in FBIO in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
55 investment managers reported holding FBIO in SEC Form 13F filings for Q2 2026.
No congressional trades in FBIO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).